Daniel Braun

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Kenneth B. Gordon, Andrew Blauvelt, Kim Papp et al. · New England Journal of Medicine · 2016 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

C.E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet · 2015 · 831 citations

Medicine, Immunology, Pharmacotherapy +10

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

Philip J. Mease, Désirée van der Heijde, Masato Okada et al. · Annals of the Rheumatic Diseases · 2016 · 568 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Mark C. Genovese, Maria Greenwald, Chul‐Soo Cho et al. · Arthritis & Rheumatology · 2014 · 205 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Anne Gill, Byron J. Hoogwerf, Jude Burger et al. · Cardiovascular Diabetology · 2010 · 135 citations · Full text

Medicine, Endocrinology, Pharmacology +17